Wednesday, July 8, 2026

Drug profile · INN

chlorzoxazone

chlorzoxazone (CHLORZOXAZONE) is a intermediate conductance calcium-activated potassium channel protein 4 opener. Associated with Teva Pharma GmbH. Route of administration: oral. Current US regulatory status: approved.

FDA: approved
US status approved
Patents linked 0
Pipeline programs 0
News articles 0
Drug details — chlorzoxazone
US status
approved
Class
Route
ORAL
Patents
0
Programs
0
Data quality
0.89

Quick answer

chlorzoxazone (CHLORZOXAZONE) is a intermediate conductance calcium-activated potassium channel protein 4 opener. Associated with Teva Pharma GmbH. Route of administration: oral. Current US regulatory status: approved.

Key facts

INN chlorzoxazone
Brand CHLORZOXAZONE
Mechanism Intermediate conductance calcium-activated potassium channel protein 4 opener
Target Intermediate conductance calcium-activated potassium channel protein 4
Route ORAL
Formulation TABLET

Mechanism of action

Intermediate conductance calcium-activated potassium channel protein 4 opener

Primary target: Intermediate conductance calcium-activated potassium channel protein 4

Approval history

Authority Status Date
FDA approved

Frequently asked questions

What is chlorzoxazone?

chlorzoxazone (CHLORZOXAZONE) is a intermediate conductance calcium-activated potassium channel protein 4 opener. Associated with Teva Pharma GmbH. Route of administration: oral. Current US regulatory status: approved.

What is the brand name for chlorzoxazone?

CHLORZOXAZONE is a marketed brand name for chlorzoxazone. Check FDA Drugs@FDA for the current US label holder and prescribing information.

What is the US approval status of chlorzoxazone?

chlorzoxazone has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.